Aiming For Better, Cheaper ERT Drugs, Oxyrane Raises $26.5 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K biotech Oxyrane raises $26.5 million D round to advance enzyme replacement therapies and validate a technology platform that may lead to cheaper-to-produce and more effective ERTs
You may also be interested in...
Euro Crisis Hits Investor Risk Appetite, But Opportunities Remain
There are good-value opportunities in Europe for VCs with money to invest, but those seeking new funds face an unprecedentedly tough challenge that’s compounded by euro uncertainty.
As Pharma Falters, Shire Specialist Model Hits Sweet Spot
With product sales growth that most big pharmas can only dream of, Shire's specialist model is working.
Sanofi Says Genzyme Integration Is On Track, But Fabrazyme Production Won't Meet Goals
Full production of the rare disease drug is pushed back a quarter, but analysts warm to Sanofi's full-year guidance and ability to meet overall goals for R&D and Genzyme integration.